Associated Papers
SPARC: a structural pathogenicity algorithm for risk classification of hERG variants.
Chatelain FC et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 2026
Mechano-Electrical Feedback in Transgenic Rabbit Models of Long QT Syndrome Type 2 and Short QT Syndrome Type 1.
Alerni N et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 2026
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome.
Nimani S et al.
European Heart Journal, 2026
Gene-therapy in inherited channelopathies like short-QT syndrome: a robust direction towards precision medicine.
Hamdani N et al.
European Heart Journal, 2026
Noncanonical pharmacological inhibition of the hERG K+ channel by a synthetic cannabinoid.
Cheng H et al.
Biochemical Pharmacology, 2025
Molecular determinants of HERG potassium channel blockade by domiphen bromide and benzethonium chloride.
Tang F et al.
Pflugers Archiv : European Journal of Physiology, 2025
Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.
Karakasis P et al.
Medical Sciences (basel, Switzerland), 2025
Molecular insights into the rescue mechanism of an HERG activator against severe LQT2 mutations.
Kumawat A et al.
Journal of Biomedical Science, 2025
The Uncommon Phenomenon of Short QT Syndrome: A Scoping Review of the Literature.
Boulmpou A et al.
Journal of Personalized Medicine, 2025
Interpreting the actionable clinical role of rare variants associated with short QT syndrome.
Martínez-Barrios E et al.
Human Genetics, 2024
Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.
Zhang Y et al.
Cellular and Molecular Life Sciences : Cmls, 2024
Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models.
Bodi I et al.
Cardiovascular Research, 2024
Investigating Inherited Heart Diseases Using Human Induced Pluripotent Stem Cell-Based Models.
Wang BX
Life (basel, Switzerland), 2024
MPA-MutPred: a novel strategy for accurately predicting the binding affinity change upon mutation in membrane protein complexes.
Ridha F et al.
Briefings in Bioinformatics, 2024
Potassium dependent structural changes in the selectivity filter of HERG potassium channels.
Lau CHY et al.
Nature Communications, 2024
Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.
Zhao Z et al.
Ebiomedicine, 2024
Gene and stem cell therapy for inherited cardiac arrhythmias.
Zhang ZH et al.
Pharmacology & Therapeutics, 2024
Dissecting the associations of KCNH2 genetic polymorphisms with various types of cardiac arrhythmias.
Li S et al.
Gene, 2024
Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues.
Maurissen TL et al.
Scientific Reports, 2024
Human Genetics of Cardiac Arrhythmias.
Schulze-Bahr E et al.
Advances in Experimental Medicine and Biology, 2024
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions.
Joshi J et al.
Frontiers in Physiology, 2024
Evaluating pro-arrhythmogenic effects of the T634S-hERG mutation: insights from a simulation study.
Hu W et al.
Interface Focus, 2023
Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome.
Shiti A et al.
Journal of Molecular and Cellular Cardiology, 2023
New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models.
Sharma AK et al.
Scientific Reports, 2023
Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.
Helliwell MV et al.
Pharmaceuticals (basel, Switzerland), 2023
Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome.
Hancox JC et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 2023
Identification of a novel pathogenic variant in KCNH2 in an Iranian family with long QT syndrome 2 by whole-exome sequencing.
Fazelifar AF et al.
Journal of Arrhythmia, 2023
hERG1 channel subunit composition mediates proton inhibition of rapid delayed rectifier potassium current (IKr) in cardiomyocytes derived from hiPSCs.
Ukachukwu CU et al.
The Journal of Biological Chemistry, 2023
Role of Ca2+ in healthy and pathologic cardiac function: from normal excitation-contraction coupling to mutations that cause inherited arrhythmia.
Keefe JA et al.
Archives of Toxicology, 2023
A need for exhaustive and standardized characterization of ion channels activity. The case of KV11.1.
Alameh M et al.
Frontiers in Physiology, 2023
Suppression and Replacement Gene Therapy for KCNH2-Mediated Arrhythmias.
Bains S et al.
Circulation. Genomic and Precision Medicine, 2022
Computational analysis of arrhythmogenesis in KCNH2 T618I mutation-associated short QT syndrome and the pharmacological effects of quinidine and sotalol.
Zhang S et al.
Npj Systems Biology and Applications, 2022
STRAIGHT-IN enables high-throughput targeting of large DNA payloads in human pluripotent stem cells.
Blanch-Asensio A et al.
Cell Reports Methods, 2022
Electromechanical reciprocity and arrhythmogenesis in long-QT syndrome and beyond.
Odening KE et al.
European Heart Journal, 2022
Research Progress and Forensic Application of Postmortem Genetic Testing in Hereditary Cardiac Diseases.
Dong YM et al.
Fa Yi Xue Za Zhi, 2022
Animal Models to Study Cardiac Arrhythmias.
Blackwell DJ et al.
Circulation Research, 2022
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.
Walsh R et al.
European Heart Journal, 2022
Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1.
Xu Q et al.
Journal of Cardiovascular Development and Disease, 2022
Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C et al.
Biochemical and Biophysical Research Communications, 2022
Preclinical short QT syndrome models: studying the phenotype and drug-screening.
Fan X et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 2022